Although DEX exposure was predicted to be more than 3 times higher in CP-C individuals, no dose adjustments seem necessary in patients with LD considering DEX’s low hepatic extraction, the low dose administered in the COVID-19 protocol and short period of treatment (10 days), and the therapeutic index of DEX. Here, CP is linked to COVID-19.